GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » Net Income

Bloomios (Bloomios) Net Income : $-39.61 Mil (TTM As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Bloomios Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Bloomios's Net Income for the three months ended in Sep. 2023 was $-26.03 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-39.61 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Bloomios's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.42.


Bloomios Net Income Historical Data

The historical data trend for Bloomios's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios Net Income Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.01 -0.02 -2.01 -13.77

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 -8.55 -2.74 -2.29 -26.03

Bloomios Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Bloomios's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-13.774+0+0+0
=-13.77

Bloomios's Net Income for the quarter that ended in Sep. 2023 is calculated as

Net Income(Q: Sep. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-26.033+0+0+0
=-26.03

Net Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomios  (OTCPK:BLMS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Bloomios's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Bloomios Net Income Related Terms

Thank you for viewing the detailed overview of Bloomios's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomios (Bloomios) Business Description

Traded in Other Exchanges
N/A
Address
701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Executives
Douglas S Rohrer officer: Chief Business Officer 701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc 10 percent owner 201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam 10 percent owner 104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile 10 percent owner 12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc 10 percent owner 201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc 10 percent owner 1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill director, 10 percent owner, officer: Chief Executive Officer 201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass director, 10 percent owner, officer: President and Director 20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd director, officer: Chairman of the Board 8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn director, officer: President & CEO 13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll director, 10 percent owner
Van Laare Derek R officer: Secretary 6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli other: former director/officer/owner 111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson director, officer: President & Treasurer 15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000